Cancer Drug Discovery Firm Notable Nabs $40M in Series B Funding Round

NEW YORK – Notable, a Bay Area firm using automated laboratory testing, artificial intelligence, and single-cell omics for cancer drug discovery, said yesterday that it has raised $40 million in a Series B financing round to accelerate the development of its services.

The financing was co-led by B Capital Group and returning investor LifeForce Capital. Industry Ventures also participated in the round, which brings Notable’s total funding to more than $55 million.